Erol Cakmak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Erol Cakmak has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
Hilmi Ataseven
3 shared publicationsOzlem Yonem
3 shared publicationsAbdulkerim Yilmaz
Department of Gastroenterology, Cumhuriyet University Faculty of Medicine, Sivas, Turkey
1 shared publicationAli Unal
1 shared publicationBanu Demet Coskun
Department of Gastroenterology, Kayseri Training and Research Hospital, Kayseri, Turkey
1 shared publicationBulent Eser
1 shared publication
Latest Publications
- Open Access
Assessment of Treatment Effectiveness in Acute and Chronic Anal Fissures
Background and Objectives: Anal fissures are a common condition in the general population, for which there are multiple treatment options. It is essential to select the most appropriate treatment for the right patient. This study aimed to observe and evaluate the effect of topical antibiotherapy, which is widely used in the management of wounds and chronic infections, on the healing of acute and chronic anal fissures. Materials and Methods: Hospital records of 625 individuals diagnosed with an anal fissure were reviewed. Previous treatments, including 0.4% glyceryl trinitrate and 5% lidocaine, were recorded. A total of 118 patients were included: 49 patients who received additional topical metronidazole due to inflammation, induration and minimal purulent discharge, in the absence of an abscess; and 69 uncomplicated patients who received only standard treatment, as per the exclusion criteria. Results: The mean age of the participants was 41.06 ± 10.70 years. No significant differences were found between the groups regarding age or sex (p = 0.616 and p = 0.665, respectively). However, prior treatment history and mucosal healing differed significantly between the two groups (p = 0.001 and p = 0.024, respectively). There were no significant differences in follow-up intervals, additional treatment requirements or improvement in VAS scores (p = 0.546, 0.904 and 0.154, respectively). Conclusions: Topical metronidazole may be associated with improved mucosal healing in selected patients with acute anal fissures presenting with clinical features such as local inflammation, minimal discharge or incision-related changes. However, the observed benefit does not appear to be uniform across all patients, and, in the absence of microbiological data, the extent of microbial involvement remains uncertain. Accordingly, topical metronidazole may be considered for carefully selected cases of acute anal fissure based on clinical judgement, while avoiding routine or indiscriminate antibiotic use.
Open AccessAssessment of Treatment Effectiveness in Acute and Chronic Anal Fissures
Background and Objectives: Anal fissures are a common condition in the general population, for which there are multiple treatment options. It is essential to select the most appropriate treatment for the right patient. This study aimed to observe and evaluate the effect of topical antibiotherapy, which is widely used in the management of wounds and chronic infections, on the healing of acute and chronic anal fissures. Materials and Methods: Hospital records of 625 individuals diagnosed with an anal fissure were reviewed. Previous treatments, including 0.4% glyceryl trinitrate and 5% lidocaine, were recorded. A total of 118 patients were included: 49 patients who received additional topical metronidazole due to inflammation, induration and minimal purulent discharge, in the absence of an abscess; and 69 uncomplicated patients who received only standard treatment, as per the exclusion criteria. Results: The mean age of the participants was 41.06 ± 10.70 years. No significant differences were found between the groups regarding age or sex (p = 0.616 and p = 0.665, respectively). However, prior treatment history and mucosal healing differed significantly between the two groups (p = 0.001 and p = 0.024, respectively). There were no significant differences in follow-up intervals, additional treatment requirements or improvement in VAS scores (p = 0.546, 0.904 and 0.154, respectively). Conclusions: Topical metronidazole may be associated with improved mucosal healing in selected patients with acute anal fissures presenting with clinical features such as local inflammation, minimal discharge or incision-related changes. However, the observed benefit does not appear to be uniform across all patients, and, in the absence of microbiological data, the extent of microbial involvement remains uncertain. Accordingly, topical metronidazole may be considered for carefully selected cases of acute anal fissure based on clinical judgement, while avoiding routine or indiscriminate antibiotic use.
- Open Access
- 1 January 2022
- Published by Elsevier in Annals of Hepatology
- Vol. 27 (1) , 100544
A novel non-invasive score for the prediction of advanced fibrosis in patients with chronic hepatitis B
- 1 January 2022
- Published by Elsevier in Annals of Hepatology
- Vol. 27 (1) , 100544
Open AccessA novel non-invasive score for the prediction of advanced fibrosis in patients with chronic hepatitis B
- 8 September 2021
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 54 (08) , E423-E424
Endoscopic closure of duodenocolic fistula by using an over-the-scope clip
A 61-year-old woman was admitted to the hospital because of persistent vomiting and diarrhea for the past year. In esophagogastroduodenoscopy performed for the etiology of these symptoms, a fistula was seen in the descending part of the duodenum without any erosion and ulceration. The fistula mouth was about 8 mm wide, and endoscopy was used to view the transverse colon from the fistula mouth ([Fig. 1]). Colonoscopy revealed the fistula mouth in the hepatic flexure and diverticulum nearby ([Fig. 2]). No additional pathology such as tumors or ulcers was seen in the duodenum and colon. During esophagogastroduodenoscopy, the fistula on the descending part of the duodenum was closed by performing suction and using an over-the-scope (OTS) clip (12/6/t; Ovesco Endoscopy AG, Tubingen, Germany) ([Fig. 3]; [Video 1]). When the fistula mouth was checked with colonoscopy, it was observed to be closed ([Fig. 4]). Oral intake started the day after the procedure and there were no problems. As a result, in selected cases, an OTS clip is an effective and safe method in full-thickness closure of transmural defects such as duodenocolic fistula [1] [2] [3] [4]. Video 1 Duodenocolic fistula treated with over-the-scope clip (12/6t). Endoscopy_UCTN_Code_CCL_1AB_2AC_3AF Publication Date: 08 September 2021 (online) © 2021. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 8 September 2021
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 54 (08) , E423-E424
Endoscopic closure of duodenocolic fistula by using an over-the-scope clip
A 61-year-old woman was admitted to the hospital because of persistent vomiting and diarrhea for the past year. In esophagogastroduodenoscopy performed for the etiology of these symptoms, a fistula was seen in the descending part of the duodenum without any erosion and ulceration. The fistula mouth was about 8 mm wide, and endoscopy was used to view the transverse colon from the fistula mouth ([Fig. 1]). Colonoscopy revealed the fistula mouth in the hepatic flexure and diverticulum nearby ([Fig. 2]). No additional pathology such as tumors or ulcers was seen in the duodenum and colon. During esophagogastroduodenoscopy, the fistula on the descending part of the duodenum was closed by performing suction and using an over-the-scope (OTS) clip (12/6/t; Ovesco Endoscopy AG, Tubingen, Germany) ([Fig. 3]; [Video 1]). When the fistula mouth was checked with colonoscopy, it was observed to be closed ([Fig. 4]). Oral intake started the day after the procedure and there were no problems. As a result, in selected cases, an OTS clip is an effective and safe method in full-thickness closure of transmural defects such as duodenocolic fistula [1] [2] [3] [4]. Video 1 Duodenocolic fistula treated with over-the-scope clip (12/6t). Endoscopy_UCTN_Code_CCL_1AB_2AC_3AF Publication Date: 08 September 2021 (online) © 2021. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- Open Access
- 17 January 2021
- Published by Wiley in Liver International
- Vol. 41 (5) , 905-914
Chanarin‐Dorfman Syndrome: A comprehensive review
The Chanarin–Dorfman syndrome (CDS) is a rare, autosomal recessively inherited genetic disease. This syndrome is associated with a decrease in the lipolysis activity in multiple tissue cells because of recessive mutations in the abhydrolase domain containing 5 (ABHD5) gene, which leads to the accumulation of lipid droplets in multiple types of cells. Major clinical symptoms in patients with CDS include ichthyosis and intracytoplasmic lipid droplets. The variability of clinical symptoms in patients with CDS depends on a large number of mutations involved. In this syndrome, liver involvement is an important cause of mortality and morbidity. This review aims to summarize the demographic characteristic, clinical symptoms, liver involvement and mutations in CDS patients in the literature to date.
- 17 January 2021
- Published by Wiley in Liver International
- Vol. 41 (5) , 905-914
Open AccessChanarin‐Dorfman Syndrome: A comprehensive review
The Chanarin–Dorfman syndrome (CDS) is a rare, autosomal recessively inherited genetic disease. This syndrome is associated with a decrease in the lipolysis activity in multiple tissue cells because of recessive mutations in the abhydrolase domain containing 5 (ABHD5) gene, which leads to the accumulation of lipid droplets in multiple types of cells. Major clinical symptoms in patients with CDS include ichthyosis and intracytoplasmic lipid droplets. The variability of clinical symptoms in patients with CDS depends on a large number of mutations involved. In this syndrome, liver involvement is an important cause of mortality and morbidity. This review aims to summarize the demographic characteristic, clinical symptoms, liver involvement and mutations in CDS patients in the literature to date.
- 20 March 2018
- Published by Cumhuriyet Medical Journal in Cumhuriyet Medical Journal
- Vol. 40 (1) , 768-776
The Real-World Efficacy and Safety of Direct-Acting Oral Antiviral Treatment in Chronic Hepatitis C Genotype 1 Patients in Turkey
En tr Objective: The aim of this study was to investigate the real-world efficacy and safety in Turkey of the paritaprevir/ritonavir, ombitasvir, dasabuvir (PrOD) ± ribavirin (RBV) and ledipasvir/sofosbuvir (LDV/SOF) ± RBV combination regimens used for chronic hepatits C virus (HCV) genotype 1 patients, which is the most common form of this disease seen both in Turkey and worldwide. Method: The study included a total of 81 HCV genotype 1 patients receiving PrOD ± RBV or LDV/SOF ± RBV treatment regimens between June 2016 and October 2017. The patients were evaluated in respect of demographic, clinical and virological data, sustained virologic response (SVR) and detailed adverse events (AE). Results: The 81 HCV patients comprised 35 (43.2%) males and 46 (56.8%) females with a mean age of 62 years. All the patients were genotype 1, which is the most commonly seen genotype in Turkey, and the sub-genotypes were HCV genotype 1a in 12.3% and genotype 1b in 87.7%. The SVR12 rate of all the chronic HCV genotype 1 patients was 79 (96.4%), 98.2% in the PrOD ± RBV patients and 96% in SOF/LDV ± RBV. AEs were reported in 46 (56.8%) of the total patient group. The most common AEs were pruritus in 18 (22.2%) patients, fatigue in 17 (21%) and headache in 16 (19.8%). Conclusions: According to the real-world data obtained in this study from a single centre in our region, a high rate of SVR12 response was obtained direct-acting oral viral treatment regimens in patients with chronic HCV genotype 1 and there was seen to be excellent tolerability. Amaç: Bu çalışmanın amacı, Türkiye'de ve dünyada kronik hepatit C virüsünün (HCV) en yaygın şekli olan genotip 1 hastalarında kullanılan paritaprevir / ritonavir, ombitasvir, dasabuvir (PrOD) ± ribavirin (RBV) ve ledipasvir / sofosbuvir (LDV / SOF) ± RBV kombinasyon rejimlerinin gerçek yaşamda etkinliğini ve güvenirliğini araştırmakdı. Yöntem: Haziran 2016 ile Ekim 2017 yılları arasında, PrOD ± RBV veya LDV / SOF ± RBV tedavi rejimleri alan toplam 81 HCV genotipi 1 hasta dahil edildi. Hastalar demografik, klinik ve virolojik verileri, kalıcı virolojik yanıt (KVY) ve ayrıntılı yan etkiler değerlendirildi. Bulgular: 81 HCV hastası, 35 (% 43.2) erkek, 46 (% 56.8) kadın olup ortalama yaş 62 idi. Hastalar Türkiye'de en sık görülen genotip olan genotip 1 ve alt genotipler % 12.3 genotip 1a ve % 87.7 genotip 1b idi. Kronik HCV genotip 1 hastalarının KVY oranı 79 (% 96.4), PrOD ± RBV hastalarında % 98.2 ve SOF / LDV ± RBV'de % 96 idi. Ayrıntılı yan etki 46 (% 56.8) hastada bildirildi. Hastalarda en sık görülen yan etkiler; 18 (% 22.2) kaşıntı, 17 yorgunluk (% 21) ve 16 (% 19.8) baş ağrısı idi. Sonuç: Bu çalışmada bölgemizdeki tek bir merkezden elde edilen gerçek yaşam verilerine göre, kronik HCV genotip 1 hastalarında direkt etkili oral viral tedavi rejimleri ile yüksek KVY 12 yanıtı elde edildi ve mükemmel tolere edildiği görüldü.
- 20 March 2018
- Published by Cumhuriyet Medical Journal in Cumhuriyet Medical Journal
- Vol. 40 (1) , 768-776
The Real-World Efficacy and Safety of Direct-Acting Oral Antiviral Treatment in Chronic Hepatitis C Genotype 1 Patients in Turkey
En tr Objective: The aim of this study was to investigate the real-world efficacy and safety in Turkey of the paritaprevir/ritonavir, ombitasvir, dasabuvir (PrOD) ± ribavirin (RBV) and ledipasvir/sofosbuvir (LDV/SOF) ± RBV combination regimens used for chronic hepatits C virus (HCV) genotype 1 patients, which is the most common form of this disease seen both in Turkey and worldwide. Method: The study included a total of 81 HCV genotype 1 patients receiving PrOD ± RBV or LDV/SOF ± RBV treatment regimens between June 2016 and October 2017. The patients were evaluated in respect of demographic, clinical and virological data, sustained virologic response (SVR) and detailed adverse events (AE). Results: The 81 HCV patients comprised 35 (43.2%) males and 46 (56.8%) females with a mean age of 62 years. All the patients were genotype 1, which is the most commonly seen genotype in Turkey, and the sub-genotypes were HCV genotype 1a in 12.3% and genotype 1b in 87.7%. The SVR12 rate of all the chronic HCV genotype 1 patients was 79 (96.4%), 98.2% in the PrOD ± RBV patients and 96% in SOF/LDV ± RBV. AEs were reported in 46 (56.8%) of the total patient group. The most common AEs were pruritus in 18 (22.2%) patients, fatigue in 17 (21%) and headache in 16 (19.8%). Conclusions: According to the real-world data obtained in this study from a single centre in our region, a high rate of SVR12 response was obtained direct-acting oral viral treatment regimens in patients with chronic HCV genotype 1 and there was seen to be excellent tolerability. Amaç: Bu çalışmanın amacı, Türkiye'de ve dünyada kronik hepatit C virüsünün (HCV) en yaygın şekli olan genotip 1 hastalarında kullanılan paritaprevir / ritonavir, ombitasvir, dasabuvir (PrOD) ± ribavirin (RBV) ve ledipasvir / sofosbuvir (LDV / SOF) ± RBV kombinasyon rejimlerinin gerçek yaşamda etkinliğini ve güvenirliğini araştırmakdı. Yöntem: Haziran 2016 ile Ekim 2017 yılları arasında, PrOD ± RBV veya LDV / SOF ± RBV tedavi rejimleri alan toplam 81 HCV genotipi 1 hasta dahil edildi. Hastalar demografik, klinik ve virolojik verileri, kalıcı virolojik yanıt (KVY) ve ayrıntılı yan etkiler değerlendirildi. Bulgular: 81 HCV hastası, 35 (% 43.2) erkek, 46 (% 56.8) kadın olup ortalama yaş 62 idi. Hastalar Türkiye'de en sık görülen genotip olan genotip 1 ve alt genotipler % 12.3 genotip 1a ve % 87.7 genotip 1b idi. Kronik HCV genotip 1 hastalarının KVY oranı 79 (% 96.4), PrOD ± RBV hastalarında % 98.2 ve SOF / LDV ± RBV'de % 96 idi. Ayrıntılı yan etki 46 (% 56.8) hastada bildirildi. Hastalarda en sık görülen yan etkiler; 18 (% 22.2) kaşıntı, 17 yorgunluk (% 21) ve 16 (% 19.8) baş ağrısı idi. Sonuç: Bu çalışmada bölgemizdeki tek bir merkezden elde edilen gerçek yaşam verilerine göre, kronik HCV genotip 1 hastalarında direkt etkili oral viral tedavi rejimleri ile yüksek KVY 12 yanıtı elde edildi ve mükemmel tolere edildiği görüldü.
- Open Access
- 1 March 2018
- Published by Kare Publishing in Turkish Journal of Trauma and Emergency Surgery
- Vol. 40 (1) , 28-34
Hepatitis B Virus Reactivation in Patients with Previously Resolved Hepatitis B Treated with Rituximab-Containing Chemotherapy for B-Cell Lymphoma
- 1 March 2018
- Published by Kare Publishing in Turkish Journal of Trauma and Emergency Surgery
- Vol. 40 (1) , 28-34
Open AccessHepatitis B Virus Reactivation in Patients with Previously Resolved Hepatitis B Treated with Rituximab-Containing Chemotherapy for B-Cell Lymphoma
- Open Access
- 24 February 2018
- Published by International Scientific Information, Inc. in Medical Science Monitor
- Vol. 24, 1152-1157
Ovarian Reserve Assessment in Celiac Patients of Reproductive Age
BACKGROUND:This study aimed to investigate ovarian reserve in patients of reproductive age with Celiac disease (CD) using anti-Müllerian hormone (AMH) levels, antral follicle counts (AFCs), and ovarian volume. MATERIAL AND METHODS:We included into t...
- 24 February 2018
- Published by International Scientific Information, Inc. in Medical Science Monitor
- Vol. 24, 1152-1157
Open AccessOvarian Reserve Assessment in Celiac Patients of Reproductive Age
BACKGROUND:This study aimed to investigate ovarian reserve in patients of reproductive age with Celiac disease (CD) using anti-Müllerian hormone (AMH) levels, antral follicle counts (AFCs), and ovarian volume. MATERIAL AND METHODS:We included into t...
- Open Access
- 28 November 2015
- Published by Brieflands in Hepatitis Monthly
- Vol. 15 (11) , e32655
Association Between the Severity of Nocturnal Hypoxia in Obstructive Sleep Apnea and Non-Alcoholic Fatty Liver Damage
Background: Obstructive sleep apnea (OSA) is a major disease that can cause significant mortality and morbidity. Chronic intermittent hypoxia is a potential causal factor in the progression from fatty liver to nonalcoholic steatohepatitis. Objectives: This study evaluated the association between the degree of liver steatosis and severity of nocturnal hypoxia. Patients and Methods: In this study, between December 2011 and December 2013, patients with ultrasound-diagnosed NAFLD evaluated by standart polysomnography were subsequentally recorded. Patients with alcohol use, viral hepatitis and other chronic liver diseases were excluded. We analyzed polysomnographic parameters, steatosis level and severity of obstructive sleep apnea (OSA) in consideration of body mass index (BMI), biochemical tests and ultrasonographic liver data of 137 subjects. Patients with sleep apnea and AHI scores of < 5, 5 - 14, 15 - 29 and ≥30 are categorized as control, mild, moderate and severe, respectively. Results: One hundred and thirty-seven patients (76 women, 61 men) with a mean age of 55.75 ± 10.13 years who underwent polysomnography were included in the study. Of 118 patients diagnosed with OSA, 19 (16.1%) had mild OSA, 39 (33.1%) moderate OSA and 60 (50.8%) severe OSA. Nineteen cases formed the control group. Apnea/hypopnea index and oxygen desaturation index (ODI) values were significantly higher in moderate and severe non-alcoholic fatty liver disease (NAFLD) compared to the non-NAFLD group. Mean nocturnal SpO2 values were significantly lower in mild NAFLD and severe NAFLD compared to the non-NAFLD group. Lowest O2 saturation (LaSO2) was found low in mild, moderate and severe NAFLD compared to the non-NAFLD group in a statistically significant manner. Conclusions: We assessed polysomnographic parameters of AHI, ODI, LaSO2 and mean nocturnal SpO2 levels, which are especially important in the association between NAFLD and OSAS. We think that it is necessary to be attentive regarding NAFLD development and progression in patients with OSA whose nocturnal hypoxia is severe. Keywords: Sleep Apnea; Obstructive; Non-Alcoholic Fatty Liver Disease; Hypoxia
- 28 November 2015
- Published by Brieflands in Hepatitis Monthly
- Vol. 15 (11) , e32655
Open AccessAssociation Between the Severity of Nocturnal Hypoxia in Obstructive Sleep Apnea and Non-Alcoholic Fatty Liver Damage
Background: Obstructive sleep apnea (OSA) is a major disease that can cause significant mortality and morbidity. Chronic intermittent hypoxia is a potential causal factor in the progression from fatty liver to nonalcoholic steatohepatitis. Objectives: This study evaluated the association between the degree of liver steatosis and severity of nocturnal hypoxia. Patients and Methods: In this study, between December 2011 and December 2013, patients with ultrasound-diagnosed NAFLD evaluated by standart polysomnography were subsequentally recorded. Patients with alcohol use, viral hepatitis and other chronic liver diseases were excluded. We analyzed polysomnographic parameters, steatosis level and severity of obstructive sleep apnea (OSA) in consideration of body mass index (BMI), biochemical tests and ultrasonographic liver data of 137 subjects. Patients with sleep apnea and AHI scores of < 5, 5 - 14, 15 - 29 and ≥30 are categorized as control, mild, moderate and severe, respectively. Results: One hundred and thirty-seven patients (76 women, 61 men) with a mean age of 55.75 ± 10.13 years who underwent polysomnography were included in the study. Of 118 patients diagnosed with OSA, 19 (16.1%) had mild OSA, 39 (33.1%) moderate OSA and 60 (50.8%) severe OSA. Nineteen cases formed the control group. Apnea/hypopnea index and oxygen desaturation index (ODI) values were significantly higher in moderate and severe non-alcoholic fatty liver disease (NAFLD) compared to the non-NAFLD group. Mean nocturnal SpO2 values were significantly lower in mild NAFLD and severe NAFLD compared to the non-NAFLD group. Lowest O2 saturation (LaSO2) was found low in mild, moderate and severe NAFLD compared to the non-NAFLD group in a statistically significant manner. Conclusions: We assessed polysomnographic parameters of AHI, ODI, LaSO2 and mean nocturnal SpO2 levels, which are especially important in the association between NAFLD and OSAS. We think that it is necessary to be attentive regarding NAFLD development and progression in patients with OSA whose nocturnal hypoxia is severe. Keywords: Sleep Apnea; Obstructive; Non-Alcoholic Fatty Liver Disease; Hypoxia
- 20 October 2015
- Published by Kare Publishing in Turkish Journal of Trauma and Emergency Surgery
- Vol. 37 (3) , 102-105
Prognostic Significance of P53, Bcl-2, and Fas Expression in Patients with Primary Gastrointestinal Diffuse Large B-Cell Lymphoma
- 20 October 2015
- Published by Kare Publishing in Turkish Journal of Trauma and Emergency Surgery
- Vol. 37 (3) , 102-105
Prognostic Significance of P53, Bcl-2, and Fas Expression in Patients with Primary Gastrointestinal Diffuse Large B-Cell Lymphoma